AMANTADINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H17N
Molecular Weight	151.2487
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC12CC3CC(CC(C3)C1)C2

InChI

InChIKey=DKNWSYNQZKUICI-UHFFFAOYSA-N

InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2

HIDE SMILES / InChI

Molecular Formula	C10H17N
Molecular Weight	151.2487
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6e6e111-38da-43a2-b6c4-15e69b720495

Amantadine hydrochloride has pharmacological actions as both an anti-Parkinson and an antiviral drug. The mechanism by which amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. In certain cases, amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. Data from earlier animal studies suggest that amantadine hydrochloride may have direct and indirect effects on dopamine neurons. More recent studies have demonstrated that amantadine is a weak, non-competitive NMDA receptor antagonist (K1 = 10µM). Although amantadine has not been shown to possess direct anticholinergic activity in animal studies, clinically, it exhibits anticholinergic-like side effects such as dry mouth, urinary retention, and constipation. Amantadine was approved by the FDA in 1966 as a prophylactic agent against Asian influenza, and eventually received approval for the treatment of influenza virus A in adults. In 1969, it was also discovered by accident to help reduce symptoms of Parkinson's disease, drug-induced extrapyramidal syndromes, and akathisia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate [NMDA] receptor 124 Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15800186	Antagonist 2760		10.0 µM [Ki]
Matrix protein 2 5 Target ID: CHEMBL1932894 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18669647	Inhibitor 8228

Conditions

Condition	Modality	Targets	Highest Phase	Product
Influenza A virus infection 9 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6e6e111-38da-43a2-b6c4-15e69b720495	Primary		Approved 8360	MANTADINE HYDROCHLORIDE Approved Use Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Launch Date 5.40518384E11
Parkinson's disease 225 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6e6e111-38da-43a2-b6c4-15e69b720495	Primary		Approved 8360	MANTADINE HYDROCHLORIDE Approved Use Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Launch Date 5.40518384E11

C_max

Value	Dose	Co-administered	Analyte	Population
636.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18074029	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AMANTADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.24 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		AMANTADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
6413.6 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18074029	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AMANTADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
14.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18074029	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AMANTADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
33% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		AMANTADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.8 g single, oral Overdose Dose: 0.8 g Route: oral Route: single Dose: 0.8 g Sources: https://pubmed.ncbi.nlm.nih.gov/19135627 Page: p.120	healthy, 2 n = 1 Health Status: healthy Age Group: 2 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/19135627 Page: p.120	Disc. AE: Status epilepticus, Agitation... AEs leading to discontinuation/dose reduction: Status epilepticus Agitation Diaphoresis Vomiting Sources: https://pubmed.ncbi.nlm.nih.gov/19135627 Page: p.120
3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3791133 Page: p.757	unhealthy, 23 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 23 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3791133 Page: p.757	Disc. AE: CNS toxicity... AEs leading to discontinuation/dose reduction: CNS toxicity (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/3791133 Page: p.757
10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Co-administed with:: diphenhydramine, p.o(250 mg, single) Sources: https://pubmed.ncbi.nlm.nih.gov/18821491 Page: p.174	unhealthy, 47 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 47 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/18821491 Page: p.174	Disc. AE: Ventricular tachycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/18821491 Page: p.174
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29368539 Page: p.605	unhealthy, 53.3 n = 27 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 53.3 Sex: M+F Population Size: 27 Sources: https://pubmed.ncbi.nlm.nih.gov/29368539 Page: p.605	Disc. AE: Serotonin syndrome, Dry mouth... AEs leading to discontinuation/dose reduction: Serotonin syndrome (serious, 3.7%) Dry mouth (3.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/29368539 Page: p.605
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28604926	unhealthy, 63.9 n = 63 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 63.9 Sex: M+F Population Size: 63 Sources: https://pubmed.ncbi.nlm.nih.gov/28604926	DLT: Visual hallucinations... Disc. AE: Visual hallucinations, Peripheral edema... Dose limiting toxicities: Visual hallucinations (4.8%) AEs leading to discontinuation/dose reduction: Visual hallucinations (7.9%) Peripheral edema (4.8%) Dry mouth (4.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/28604926
420 mg 1 times / day multiple, oral Highest studied dose Dose: 420 mg, 1 times / day Route: oral Route: multiple Dose: 420 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25650051 Page: p.793	unhealthy, 66.4 n = 20 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 66.4 Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/25650051 Page: p.793	Disc. AE: Hallucinations, Balance disorder... AEs leading to discontinuation/dose reduction: Hallucinations (15%) Balance disorder (5%) Confusional state (5%) Dry mouth (5%) Subdural hematoma (5%) Constipation (5%) Sources: https://pubmed.ncbi.nlm.nih.gov/25650051 Page: p.793
100 mg 3 times / day steady, oral Dose: 100 mg, 3 times / day Route: oral Route: steady Dose: 100 mg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01071395	unhealthy n = 36 Health Status: unhealthy Condition: Parkinson's disease Population Size: 36 Sources: https://clinicaltrials.gov/ct2/show/NCT01071395	Other AEs: Dry mouth... Other AEs: Dry mouth (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01071395

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inhibitor 1579	substrate 1010 inhibitor 1752	substrate 1193 inhibitor 1837

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2B6 799 CYP2C19 1463 CYP2C8 901 CYP2E1 876 CYP3A5 73 OCT1 506 OCT2 638 OCT3 149 MATE1 304 MATE2 261	CYP1A2 1032 CYP2B6 660 CYP2C19 985 CYP2C8 688 CYP2E1 648 CYP3A5 391 OCT2 348

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2B6 985	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2C8 955	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2E1 964	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP3A5 130	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
MATE1 306	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/19164462/	yes [Ki 111.8 uM]
MATE2 261	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/19164462/	yes [Ki 1167 uM]
OCT1 523	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16581093/	yes [Ki 236 uM]
OCT2 639	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16581093/	yes [Ki 284 uM]
OCT3 149	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16581093/	yes [Ki >1000 uM]

Drug as victim

Target	Modality	Activity
CYP1A2 1032	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2B6 660	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2C19 985	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2C8 688	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2C9 1010	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2D6 1193	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP2E1 648	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
CYP3A5 391	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208944Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	unlikely
OCT2 348	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/9687576/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:2618	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2618
ChemicalBook	CB3259991	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3259991
MolPort	MolPort-001-661-700	https://www.molport.com/shop/molecule-link/MolPort-001-661-700
MolPort	MolPort-020-000-111	https://www.molport.com/shop/molecule-link/MolPort-020-000-111
ZINC	ZINC000000968256	http://zinc15.docking.org/substances/ZINC000000968256
eMolecules	27515804	https://www.emolecules.com/cgi-bin/more?vid=27515804
eMolecules	476391	https://www.emolecules.com/cgi-bin/more?vid=476391

PubMed

Title	Date	PubMed
Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.	1991 Dec	1725692
Neurotoxicity of chlorpromazine and modulation by amantadine as a function of mouse strain.	1991 Fall	1745440
Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?	1992	1320514
A trigger for Tourette's syndrome.	1992 Mar	1564044
Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease.	1992 Nov	1295627
Amantadine-induced multiple spike waves on an electroencephalogram of a schizophrenic patient.	2000 Jan	12611370
Heterocyclic rimantadine analogues with antiviral activity.	2003 Dec 1	14642592
An artist's view of drug-induced hallucinosis.	2003 Jul	12815666
Synthesis of 1-boraadamantaneamine derivatives with selective astrocyte vs C6 glioma antiproliferative activity. A novel class of anti-hepatitis C agents with potential to bind CD81.	2003 Jul 3	12825926
Noncompetitive antagonist binding sites in the torpedo nicotinic acetylcholine receptor ion channel. Structure-activity relationship studies using adamantane derivatives.	2003 Jun 24	12809491
Risperidone treatment of motor restlessness following anoxic brain injury.	2003 Mar	12623500
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.	2003 May 19	12729645
Livedo reticularis induced by amantadine.	2003 Sep	14511008
Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.	2004 Aug	15456080
Bitterness evaluation of medicines for pediatric use by a taste sensor.	2004 Aug	15304986
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.	2004 Aug	15299154
Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study.	2004 Jan	14695734
Motor-learning impairment by amantadine in healthy volunteers.	2004 Jan	14532914
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.	2004 Jul	15004218
New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.	2004 Jun	15166629
Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging.	2004 Mar	14960538
[Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model].	2004 Mar-Apr	15188753
Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults.	2004 Nov	15566030
Prevention of influenza in the general population.	2004 Nov 9	15534315
The potential anti-hBV effect of amantadine in combination with ursodeoxycholic acid and biphenyl dimethyl dicarboxylate in hepG2 2.2.15 cells.	2005 Apr	15918519
Improved neurological function after Amantadine treatment in two patients with brain injury.	2005 Apr	15769570
Site-isolated porphyrin catalysts in imprinted polymers.	2005 Aug 19	15977282
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.	2005 Dec	16203001
High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.	2005 Feb 1	15652229
Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12.	2005 Jul	15930894
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.	2005 Jul	15899244
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.	2005 Nov	16154788
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.	2005 Sep	16258207
Determination of serum amantadine by liquid chromatography-tandem mass spectrometry.	2005 Sep	15913590
Glutamate receptors in neuroinflammatory demyelinating disease.	2006	16883070
Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts.	2006 Feb	16428939
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection.	2006 Feb 14	16439866
[Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten].	2006 Jul	16915929
The pharmacology of aminoadamantane nitrates.	2006 Jul	16842096
Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.	2006 Jul	16364413
Amantadine-induced livedo reticularis: a report of two cases.	2006 Mar	16573266
Hiccups associated with dopamine agonists in Parkinson disease.	2006 Mar 14	16534128
Interferon signal transduction of biphenyl dimethyl dicarboxylate/amantadine and anti-HBV activity in HepG2 2.2.15.	2006 May	16756086
Simultaneous liquid chromatographic assay of amantadine and its four related compounds in phosphate-buffered saline using 4-fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorescent derivatization reagent.	2006 May	16161183
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.	2006 Nov	16960862
Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice.	2006 Sep	16835770
Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.	2006 Sep 15	16978399
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.	2007 Apr 16	17306893
19F NMR detection of the complex between amantadine and the receptor portion of the influenza A M2 ion channel in DPC micelles.	2007 Jul 15	17502147

Patents

Sample Use Guides

In Vivo Use Guide

Uncomplicated Influenza A Virus Illness: Adult: 200 mg; two 100 mg capsules as a single daily dose. The daily dosage may be split into one capsule of 100 mg twice a day. In persons 65 years of age or older, the daily dosage is 100 mg. Parkinsonism: Adult: is 100 mg twice a day when used alone. Amantadine Hydrochloride Capsules have an onset of action usually within 48 hours. The initial dose is 100 mg daily for patients with serious associated medical illnesses or who are receiving high doses of other antiparkinson drugs. After one to several weeks at 100 mg once daily, the dose may be increased to 100 mg twice daily, if necessary.

Route of Administration: Oral

In Vitro Use Guide

Amantadine markedly inhibited the proliferation of HepG2 and SMMC‑7721 cells in a dose‑ and time‑dependent manner and arrested the cell cycle at the G0/G1 phase

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:46:32 UTC 2023` Edited by `admin` on `Wed Jul 05 22:46:32 UTC 2023`
Record UNII	BF4C9Z1J53
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMANTADINE

Official Name

English

GOCOVRI

Brand Name

English

AMANTADINE [MI]

Common Name

English

AMANTADINE [MART.]

Common Name

English

AMANTADINE [VANDF]

Common Name

English

ADAMANTAN-1-AMINE

Systematic Name

English

amantadine [INN]

Common Name

English

NSC-341865

Code

English

AMANTIDINE

Common Name

English

Amantadine [WHO-DD]

Common Name

English

AMANTADINE [HSDB]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C93038